Evidence map›Paper›PMID 32130679›Full record

ArticleDrugs in R&D2020

Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations.

Sanela Tarabar, Debra Kelsh, Bradley Vince, Rina Leyva, Dongweon Song, Kyle Matschke, David E Kellstein, Suzanne Meeves, Mario Cruz-Rivera

Open access · goldAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph

Article in Drugs in R&D, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sanela TarabarPfizer New Haven Clinical Research Unit, New Haven, CT, USA. Sanela.Tarabar@pfizer.com.
Debra KelshAltasciences/Vince and Associates Clinical Research, Overland Park, KS, USA.
Bradley VinceAltasciences/Vince and Associates Clinical Research, Overland Park, KS, USA.
Rina LeyvaPfizer Consumer Healthcare, Madison, NJ, USA.
Dongweon SongPfizer Inc., Collegeville, PA, USA.
Kyle MatschkePfizer Inc., Collegeville, PA, USA.
David E KellsteinPfizer Consumer Healthcare, Madison, NJ, USA.
Suzanne MeevesPfizer Consumer Healthcare, Madison, NJ, USA.
Mario Cruz-RiveraPfizer Consumer Healthcare, Madison, NJ, USA.
Pfizer (United States) · USAltasciences Clinical Research Vince & Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA fixed-dose combination (FDC) of ibuprofen and acetaminophen has been developed that provides greater analgesic efficacy than either agent alone at the same doses without increasing the risk for adverse events.

methodsWe report three clinical phase I studies designed to assess the pharmacokinetics (PK) of the FDC of ibuprofen/acetaminophen 250/500 mg (administered as two tablets of ibuprofen 125 mg/acetaminophen 250 mg) in comparison with its individual components administered alone or together, and to determine the effect of food on the PK of the FDC. Two studies in healthy adults aged 18-55 years used a crossover design in which subjects received a single dose of each treatment with a 2-day washout period between each. In the third study, the bioavailability of ibuprofen and acetaminophen from a single oral dose of the FDC was assessed in healthy adolescents aged 12-17 years, inclusive.

resultsA total of 35 and 46 subjects were enrolled in the two adult studies, respectively, and 21 were enrolled in the adolescent study. Ibuprofen and acetaminophen in the FDC were bioequivalent to the monocomponents administered alone or together. With food, the maximum concentration (C

conclusionsThe FDC of ibuprofen/acetaminophen 250/500 mg has a PK profile similar to its monocomponent constituents when administered separately or coadministered, indicating no drug-drug interactions and no formulation effects. Similar to previous findings for the individual components, the rates of absorption of ibuprofen and acetaminophen from the FDC were slightly delayed in the presence of food. Overall, adolescents had similar exposures to acetaminophen and ibuprofen as adults, while younger adolescents had slightly greater exposure than older adolescents, probably due to their smaller body size. The FDC was generally well tolerated.

Indexed as

AcetaminophenAdministration, OralAdolescentAdultAnalgesics, Non-NarcoticCross-Over StudiesDose-Response Relationship, DrugDrug CombinationsFemaleHumansIbuprofenMaleMiddle AgedYoung AdultAcetaminophenAnalgesics, Non-NarcoticDrug CombinationsIbuprofen

Identifiers

PMID32130679
PMCPMC7067710
OpenAlexW3009901316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.